Top

Published in:

01-09-2014 | Letter to the Editor

Pathological features of breast and ovarian cancers in RAD51C germline mutation carriers

Authors: Heidrun Gevensleben, Verena Bossung, Alfons Meindl, Barbara Wappenschmidt, Nikolaus de Gregorio, Ana Osorio, Atocha Romero, Reinhard Buettner, Birgid Markiefka, Rita Katharina Schmutzler

Published in: Virchows Archiv | Issue 3/2014

Excerpt

To the Editor: …

Available only for authorised users

Meindl A, Hellebrand H, Wiek C, Erven V, Wappenschmidt B, Niederacher D, Freund M, Lichtner P, Hartmann L, Schaal H, Ramser J, Honisch E, Kubisch C, Wichmann HE, Kast K, Deissler H, Engel C, Muller-Myhsok B, Neveling K, Kiechle M, Mathew CG, Schindler D, Schmutzler RK, Hanenberg H (2010) Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene. Nat Genet 42(5):410–414. doi:10.1038/ng.569 PubMedCrossRef

Palacios J, Honrado E, Osorio A, Cazorla A, Sarrio D, Barroso A, Rodriguez S, Cigudosa JC, Diez O, Alonso C, Lerma E, Sanchez L, Rivas C, Benitez J (2003) Immunohistochemical characteristics defined by tissue microarray of hereditary breast cancer not attributable to BRCA1 or BRCA2 mutations: differences from breast carcinomas arising in BRCA1 and BRCA2 mutation carriers. Clin Cancer Res 9(10 Pt 1):3606–3614PubMed

Pelttari LM, Heikkinen T, Thompson D, Kallioniemi A, Schleutker J, Holli K, Blomqvist C, Aittomaki K, Butzow R, Nevanlinna H (2011) RAD51C is a susceptibility gene for ovarian cancer. Hum Mol Genet 20(16):3278–3288. doi:10.1093/hmg/ddr229 PubMedCrossRef

Cunningham JM, Cicek MS, Larson NB, Davila J, Wang C, Larson MC, Song H, Dicks EM, Harrington P, Wick M, Winterhoff BJ, Hamidi H, Konecny GE, Chien J, Bibikova M, Fan JB, Kalli KR, Lindor NM, Fridley BL, Pharoah PP, Goode EL (2014) Clinical characteristics of ovarian cancer classified by BRCA1, BRCA2, and RAD51C status. Sci Rep 4:4026. doi:10.1038/srep04026 PubMedCrossRef

Ozretic L, Rhiem K, Huss S, Wappenschmidt B, Markiefka B, Sinn P, Schmutzler RK, Buettner R (2011) High nuclear poly(adenosine diphosphate-ribose) polymerase expression is predictive for BRCA1- and BRCA2-deficient breast cancer. J Clin Oncol 29(34):4586–4588. doi:10.1200/JCO.2011.38.1988, author reply 4588PubMedCrossRef

Schnurbein G, Hauke J, Wappenschmidt B, Weber-Lassalle N, Engert S, Hellebrand H, Garbes L, Becker A, Neidhardt G, Rhiem K, Meindl A, Schmutzler RK, Hahnen E (2013) RAD51C deletion screening identifies a recurrent gross deletion in breast cancer and ovarian cancer families. Breast Cancer Res 15(6):R120. doi:10.1186/bcr3589 PubMedCentralPubMedCrossRef

Title: Pathological features of breast and ovarian cancers in RAD51C germline mutation carriers
Authors: Heidrun Gevensleben
Verena Bossung
Alfons Meindl
Barbara Wappenschmidt
Nikolaus de Gregorio
Ana Osorio
Atocha Romero
Reinhard Buettner
Birgid Markiefka
Rita Katharina Schmutzler
Publication date: 01-09-2014
Publisher: Springer Berlin Heidelberg
Published in: Virchows Archiv / Issue 3/2014
Print ISSN: 0945-6317
Electronic ISSN: 1432-2307
DOI: https://doi.org/10.1007/s00428-014-1619-1

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Pathological features of breast and ovarian cancers in RAD51C germline mutation carriers

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 3/2014

Immunologic and metabolic characteristics of HPV-negative and HPV-positive head and neck squamous cell carcinomas are strikingly different

Frequency and clinicopathological features of fibroelastotic changes in the gastrointestinal tract

Duodenal gastric heterotopia, sporadic or fundic gland polyp-associated, frequently carries β-catenin mutation

Absence of caveolin-1 expression in carcinoma-associated fibroblasts of invasive micropapillary carcinoma of the breast predicts poor patient outcome

Increased lymphangiogenesis in Riedel thyroiditis (Immunoglobulin G4-related thyroid disease)

Expression of PD-1 (CD279) and FoxP3 in diffuse large B-cell lymphoma